Patents Assigned to The Rockefeller University
  • Publication number: 20180079800
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 22, 2018
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Patent number: 9890207
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: February 13, 2018
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Patent number: 9879068
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 30, 2018
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
  • Publication number: 20180002444
    Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
    Type: Application
    Filed: December 21, 2015
    Publication date: January 4, 2018
    Applicant: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
  • Publication number: 20170362664
    Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
    Type: Application
    Filed: June 22, 2017
    Publication date: December 21, 2017
    Applicant: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Kim Png
  • Patent number: 9845358
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 19, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Patent number: 9840533
    Abstract: The present disclosure provides, among other things, novel cyclic-GMP-AMP (cGAMP) analogs, mimics, mimetics and variants, and compositions and kits thereof; methods of using the compounds as described herein for treating cancer, and immune disease, disorders, or conditions; methods of using the compounds as described herein for modulating cGAS and STING; and methods of designing or characterizing a cGAS modulator.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: December 12, 2017
    Assignees: Memorial Sloan Kettering Cancer Center, Rutgers, The State University of New Jersey, The Rockefeller University, University of Bonn
    Inventors: Dinshaw Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 9833465
    Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2-R5 and R10-R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: December 5, 2017
    Assignee: The Rockefeller University
    Inventors: Sean Brady, Hahk-Soo Kang
  • Patent number: 9822372
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: November 21, 2017
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, The Rockefeller University
    Inventors: Feng Zhang, David Benjamin Turitz Cox, Luciano Marraffini, David Olivier Bikard, Wenyan Jiang, Neville Espi Sanjana
  • Publication number: 20170319525
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 9, 2017
    Applicant: The Rockefeller University
    Inventors: Sohail F. Tavazoie, Nora Pencheva
  • Publication number: 20170296497
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 19, 2017
    Applicant: The Rockefeller University
    Inventors: Sohail Tavazoie, Jia M. Loo
  • Publication number: 20170298433
    Abstract: In one embodiment, the present invention relates to a method for optimizing cell-type specific protein expression. In another embodiment, the present invention relates to a method for creating a tRNA profile of a cell.
    Type: Application
    Filed: April 13, 2017
    Publication date: October 19, 2017
    Applicant: The Rockefeller University
    Inventors: Sohail TAVAZOIE, Hani GOODARZI
  • Patent number: 9783594
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: October 10, 2017
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Patent number: 9758573
    Abstract: The invention provides epsilon toxin (ETX) produced by Clostridium perfringens type B or type D as a causative toxin for human multiple sclerosis (MS). The invention further identifies ETX binding receptor MAL for ETX mediated cell death and other toxin-logical activities in MS. Methods and compositions to prevent humans from multiple sclerosis (MS) and/or treating MS by directly or indirectly interfering with epsilon toxin (ETX), its binding receptor (e.g., MAL), or ETX-receptor interactions so as to inhibit or suppress downstream ETX mediated receptor signaling activities are provided. Also provided are various methods to detect, diagnose, monitor, assess multiple sclerosis (MS) by determining an expression level of ETX gene or its encoding protein in human patient suspected for and/or at risk for multiple sclerosis (MS).
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: September 12, 2017
    Assignees: Cornell University, The Rockefeller University
    Inventors: Timothy Vartanian, Kareem Rashid Rumah, Vincent A. Fischetti
  • Publication number: 20170252328
    Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.
    Type: Application
    Filed: March 15, 2017
    Publication date: September 7, 2017
    Applicants: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Marilyn D. Resh, Joseph Fraser Glickman, Elissaveta Petrova, Ouathek Ouerfelli
  • Publication number: 20170253659
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: June 28, 2016
    Publication date: September 7, 2017
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Rony Dahan
  • Publication number: 20170247463
    Abstract: The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific T lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the TNFR Superfamily and thereby mimic the natural ligand for the receptor from the TNFR Superfamily. Modified antibodies of this class display enhanced immunostimulatory activity and may be formulated and administered for the treatment of a disease or disorder.
    Type: Application
    Filed: February 6, 2017
    Publication date: August 31, 2017
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Fubin Li
  • Patent number: 9731010
    Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: August 15, 2017
    Assignees: The Rockefeller University, Contrafect Corporation
    Inventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
  • Publication number: 20170210786
    Abstract: The present invention relates to methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs. Specifically, the disclosure provides methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs, the methods comprising administering to the subject a therapeutically effective amount of an isolated anti-HIV antibody, and administering to the subject two or more viral transcription inducers in effective amounts to induce transcription of an HIV provirus in the cells. Further provided are antibodies and viral transcription inducers used in the methods.
    Type: Application
    Filed: July 21, 2015
    Publication date: July 27, 2017
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Ariel Halper-Stromberg, Ching-Lan Lu
  • Patent number: 9707195
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: July 18, 2017
    Assignee: The Rockefeller University
    Inventors: Sohail F. Tavazoie, Nora Pencheva